Vincent Cottin,1 Yoshikazu Inoue,2 Martin Kolb,3 Ivan Rosas,4 Sara Tomassetti,5 Manuel Quaresma,6 Rainer-Georg Goeldner,7 Rozsa Schlenker-Herceg,8 Kevin K Brown9 on behalf of the INBUILD trial investigators
1National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France; 2Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Centre, Osaka, Japan; 3McMaster University and St. Joseph’s Healthcare, Hamilton, Ontario, Canada; 4Brigham and Women’s Hospital, Boston, MA, USA; 5Department of Diseases of the Thorax, Ospedale GB Morgagni, Forlì, Italy; 6Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 7Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; 8Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 9Department of Medicine, National Jewish Health, Denver, CO, USA
Introduction
- In patients with chronic fibrosing ILDs and a progressive phenotype, decline in forced vital capacity (FVC) is predictive of mortality.1-4
- In the INBUILD trial in subjects with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis (IPF), nintedanib slowed the rate of decline in FVC (mL/year) over 52 weeks by 57% versus placebo (difference 107.0 mL/year [95% CI: 65.4, 148.5]).5
